Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFFWD.L Regulatory News (FFWD)

  • There is currently no data for FFWD

Placing

3 Aug 2018 08:00

RNS Number : 7486W
FastForward Innovations Limited
03 August 2018
 

For Immediate Release

3 August 2018

FastForward Innovations Limited

("FastForward" or the "Company")

 

Placing

Director Dealing

 

Further to the announcement by FastForward Innovations Limited (AIM: FFWD) on 1 August 2018, the Company is pleased to announce that it has today agreed to place 30,769,230 new Ordinary Shares of 1p each (the "Placing Shares") at a price of 13p per Placing Share with a number of new and existing investors thereby raising gross proceeds of £4,000,000 (US$5,240,000 at an exchange rate of £1:US$1.31, being the rate on the date the Company determined the terms of the placing) before expenses (the "Placing"). The Placing Price represents a premium of approximately 27.7% to the Company's most recently published NAV per share of 10.18p. The Placing is being done by way of a placing through the Company's brokers and a direct subscription by the Company (together the "Placing"). The net proceeds of the Placing will be used to repay the Director's Loan announced on 23 July 2018, assist the Company in making investments in accordance with its investing policy and for general working capital purposes.

 

Subject to payment, application for the Placing Shares (which will rank pari passu with the existing Ordinary Shares) to be admitted to trading on AIM ("Admission") will be made with dealings expected to commence at 8.00 a.m. on 10 August 2018.

 

The Company expects that the enlarged issued share capital following the issue of the Placing Shares will be 166,913,727 Ordinary Shares (the "Enlarged Issued Share Capital").

 

The Company is reviewing its options to allow Shareholders the ability to subscribe for new Ordinary Shares on the same terms as the Placing and expects to update investors on this shortly.

 

Commenting on the Placing, Chief Executive Officer Lorne Abony noted:

 

"The placing funds allow the Company to take advantage of potential opportunities for new and follow on investments. I am pleased to see the support the Board and existing significant Shareholders have provided and see this as a vote of confidence in what we are building.

 

It is disappointing that the share price did not pick up after the recent newsflow, and that this round of funding is at 13p. For this reason the Board is committed to providing an opportunity for existing shareholders to also participate on the same terms. The intention had been to complete the Placing at a higher price but the share price did not react as expected after the Vogogo, Leap, Intensity and Factom investments, which the Board maintain are excellent investment opportunities. Similarly, whilst the pricing of the deal was disappointing for all concerned, the Company thanks investors for their support and will continue to pursue best in class investment opportunities inline with its investing policy, including within the Blockchain, Medical Cannabis and Artificial Intelligence sectors which the board believes offers the highest growth potential at present."

 

 

Related Party Transaction

 

Mr Lorne Abony and Mr Jim Mellon (who are each Directors of the Company) have participated in the Placing. The participation of the Directors is as set out below:

 

Name

Subscription

Placing Shares

Total Ordinary Shares (inc. Placing Shares)

 

% interest in the Enlarged Issued Share Capital (excluding those shares held in Treasury)

Lorne Abony1

£487,000

3,746,154

15,994,588

9.90%

Jim Mellon2

£761,505

5,857,731

16,283,722

10.08%

Lorne Abony's interest in shares is held by Abony Enterprises Limited Partnership, a limited partnership of which he is the majority legal owner.

Mr Mellon's interest in the Company's shares is held by Galloway Limited, a company owned by a trust of which Mr James Mellon is a life tenant, in respect of 10,425,991 shares and directly by Mr Mellon in respect of 5,857,731 shares.

 

The Directors are related parties for the purposes of the AIM Rules. The participation of the two Directors in the Placing constitutes a Related Party Transaction under Rule 13 of the AIM Rules for Companies.

 

Accordingly, Mr Ian Burns, the Company's Finance Director (Mr Edward McDermott, Non-Executive Director, is an employee of the Company's Brokers, Optiva Securities Limited, and so is not regarded as independent for the purposes of the Placing), is the independent director of the Company for the purposes of the Placing. Mr Ian Burns confirms that, having consulted with the Company's Nominated Adviser, the terms of the Placing are fair and reasonable insofar as the Company's shareholders are concerned. In particular Mr Burns notes that the Directors have participated on the same terms as all other placees.

 

The Investors

 

In addition to Mr Abony and Mr Mellon, following the issue of the Placing Shares the following shareholder will be interested in more than 3 per cent. of the Enlarged Issued Share Capital (excluding those shares held in Treasury):

 

Name

Subscription

Placing Shares

Total Ordinary Shares (inc. Placing Shares)

 

% interest in the Enlarged Issued Share Capital (excluding those shares held in Treasury)

LOM Nominees

£761,505

5,857,731

5,857,731

3.63%

 

 

Issued Shares

 

Following Admission of the Placing Shares, the Company's issued share capital consists of 166,913,727Ordinary Shares. 5,413,623 Ordinary shares are held in Treasury. For reporting under the FCA's Disclosure and Transparency Rules, Shareholders should exclude any shares held in Treasury and should use the figure of 161,500,104 Ordinary Shares (the issued voting share capital) when determining if they are required to notify their interest, or a change of their interest in the Company.

 

The Market Abuse Regulation ("MAR") became effective from 3 July 2016. Market soundings, as defined in MAR, were taken in respect of the Fundraise with the result that certain persons became aware of inside information, as permitted by MAR. That inside information is set out in this announcement and has been disclosed as soon as possible in accordance with paragraph 7 of article 17 of MAR. Therefore, those persons that received inside information in a market sounding are no longer in possession of inside information relating to the Company and its securities.

 

 

For further information on the Company please visit www.fstfwd.co or contact:

FastForward Innovations Limited

info@fstfwd.co

Sue Saunders / Ian Burns

 

Beaumont Cornish Limited (Nomad)

James Biddle / Roland Cornish

Tel: +44 207 628 3396

 

Optiva Securities Limited (Broker)

Graham Dickson Tel: +44 (0) 203 137 1902

 

 

 

DISCLAIMER

 

Beaumont Cornish Limited, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting exclusively as Nominated adviser to FastForward Innovations Limited and no one else in connection with the Placing and will not be responsible to anyone other than FastForward Innovations Limited for providing the protections afforded to clients of Beaumont Cornish Limited nor for providing advice in relation to the Placing. Neither Beaumont Cornish Limited nor any of its affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Beaumont Cornish Limited in connection with this Announcement, any statement contained herein, or otherwise.

 

CAUTIONARY STATEMENT

 

The AIM Market of London Stock Exchange plc does not accept responsibility for the adequacy or accuracy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. All statements, other than statements of historical fact, in this news release are forward-looking statements that involve various risks and uncertainties, including, without limitation, statements regarding potential values, the future plans and objectives of FastForward Innovations Limited. There can be no assurance that such statements will prove to be accurate, achievable or recognisable in the near term.

Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. FastForward Innovations Limited assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
IOEGLGDISUGBGIX
Date   Source Headline
23rd Jul 20187:00 amRNSAgreement
19th Jul 201812:40 pmRNSFurther investment in Intensity Therapeutics Inc.
9th Jul 201811:17 amRNSIncreased holding in Fralis LLC (Leap Gaming)
6th Jul 20185:44 pmRNSResults for the year ended 31st March 2018
22nd Jun 20182:30 pmRNSInvestment in Vogogo Inc. Conv. Debenture Units
20th Jun 20186:20 pmRNSInvestee Company Update
19th Jun 20187:00 amRNSInvestment in Juvenescence Limited
12th Jun 20187:00 amRNSInvestee Company Update: Subscription into Fralis
11th Jun 20189:53 amRNSSale of Aphria Shares
16th May 20187:00 amRNSRegulatory Approval
23rd Mar 20183:35 pmRNSInvestee Company Update: Nuuvera Inc.
21st Mar 20181:28 pmRNSInvestee Company Update: Nuuvera
12th Mar 20181:00 pmRNSKey Investor Document
7th Mar 20182:34 pmRNSDirector/PDMR Shareholding
7th Mar 20187:00 amRNSProposed Director's Dealing
27th Feb 20183:43 pmRNSInvestee Company Update: Intensity Therapeutics
26th Feb 20184:01 pmRNSInvestee Company Update: Nuuvera
20th Feb 20183:26 pmRNSInvestee Company Update: Nuuvera
13th Feb 201812:22 pmRNSDirector Appointment
13th Feb 201812:05 pmRNSResult of AGM
12th Feb 20184:51 pmRNSTransaction in Own Shares
6th Feb 20189:37 amRNSCorrection of Notice of AGM
2nd Feb 20189:35 amRNSInvestee Company Update: Vemo
31st Jan 201811:04 amRNSTransaction in Own Shares
30th Jan 20185:00 pmRNSNotice of AGM
30th Jan 20184:20 pmRNSNotice of AGM
30th Jan 20188:35 amRNSHolding(s) in Company
29th Jan 20181:33 pmRNSInvestee Company Update: Nuuvera
23rd Jan 20182:43 pmRNSExtension of Share Buy-back Programme
23rd Jan 20181:19 pmRNSTransaction in Own Shares
18th Jan 20183:18 pmRNSInvestment Company Updates: Nuuvera
16th Jan 20183:36 pmRNSInvestee Company Update: Nuuvera
12th Jan 20183:43 pmRNSInvestee Company Update: Nuuvera
12th Jan 20182:23 pmRNSInvestee Company Update: Nuuvera
11th Jan 20188:00 amRNSInvestee Company Update: Nuuvera
8th Jan 20187:00 amRNSInvestee Company Update: Nuuvera
2nd Jan 201811:26 amRNSInvestee Company update: Nuuverra transaction
28th Dec 20173:29 pmRNSHalf-year Report
15th Dec 20179:23 amRNSCompany Secretary Change
15th Dec 20177:00 amRNSInvestee Company Update: Nuuvera
29th Nov 20174:14 pmRNSTransaction in Own Shares
29th Nov 20177:00 amRNSHolding(s) in Company
28th Nov 20174:06 pmRNSTransaction in Own Shares
23rd Nov 201710:12 amRNSHolding(s) in Company
20th Nov 201710:30 amRNSShare Buy-Back Programme
20th Nov 20179:56 amRNSMarket Update
3rd Nov 201712:00 pmRNSInvestee Company Update
9th Oct 20177:00 amRNSUpdate on Nuuverra Investment
18th Sep 20177:00 amRNSDisposal of interest in investee company
15th Aug 20177:00 amRNSInvestee Company Update: Schoold

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.